Double maintains 1 strategies that include RVMD - Revolution Medicines, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
JAAA | 0.05% | $20.22B | 0.21% |
COM | 0.08% | $246.62M | 0.8% |
ITM | -0.08% | $1.97B | 0.18% |
MEAR | -0.13% | $771.64M | 0.25% |
TOTL | 0.15% | $3.41B | 0.55% |
IBDQ | 0.18% | $3.18B | 0.1% |
FXY | -0.24% | $400.29M | 0.4% |
MUNI | -0.25% | $1.79B | 0.35% |
CMBS | -0.25% | $445.41M | 0.25% |
CCOR | -0.28% | $71.42M | 1.18% |
EQLS | -0.32% | $7.75M | 1% |
SPSK | -0.37% | $280.69M | 0.5% |
SGOV | -0.44% | $33.02B | 0.09% |
IBTH | 0.46% | $1.36B | 0.07% |
FMB | -0.49% | $2.04B | 0.65% |
CGMU | 0.60% | $2.83B | 0.27% |
SEIX | 0.70% | $316.50M | 0.57% |
UTWO | 0.71% | $386.83M | 0.15% |
ASHR | 0.84% | $2.40B | 0.65% |
BILS | -0.94% | $3.37B | 0.1356% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 52.60% | $6.19B | 0.35% |
PTH | 50.60% | $130.98M | 0.6% |
IBB | 47.71% | $6.68B | 0.45% |
EFAA | 45.29% | $106.96M | 0% |
PBE | 43.81% | $259.08M | 0.58% |
GNOM | 43.03% | $71.39M | 0.5% |
QQA | 42.75% | $162.24M | 0% |
XPH | 42.73% | $167.37M | 0.35% |
RSPA | 41.18% | $274.94M | 0% |
BBH | 40.08% | $408.55M | 0.35% |
FBT | 39.46% | $1.22B | 0.56% |
IWO | 39.18% | $12.87B | 0.24% |
CPSJ | 38.63% | $38.01M | 0.69% |
CPRJ | 38.34% | $51.17M | 0.69% |
IWC | 38.28% | $977.29M | 0.6% |
ARKG | 37.88% | $1.25B | 0.75% |
ISCG | 37.56% | $681.17M | 0.06% |
FXH | 36.90% | $1.08B | 0.62% |
VTWO | 36.78% | $11.91B | 0.1% |
IWM | 36.57% | $74.54B | 0.19% |
Finnhub
REDWOOD CITY, Calif., Jan. 29, 2025 -- Revolution Medicines, Inc. , a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced...
SeekingAlpha
Revolution Medicines' promising KRAS inhibitors show potential in pancreatic cancer. See why we recommend a hold rating on RVMD stock.
Yahoo
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. PT. To access the live webcast of the present
Yahoo
Viewing insider transactions for Revolution Medicines, Inc.'s ( NASDAQ:RVMD ) over the last year, we see that insiders...
SeekingAlpha
Explore Baker Brothers' biotech-focused 13F portfolio, with notable stake increases in Incyte, Summit Therapeutics, and other small-cap firms. Read more here.
Yahoo
Underwriters’ full exercise of option brings gross proceeds to $862.5 millionREDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the closing of its underwritten public offering of 16,576,088 shares of its common stock at a public offering price of $46.00 per share, before underwriting discounts and commissions, and, in lieu of shar
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PSQH | -13.76% | $168.72M | -13.57% | 0.00% |
HUSA | -12.25% | $20.71M | -8.33% | 0.00% |
CBOE | -11.96% | $21.67B | +12.40% | 1.15% |
HELE | -10.08% | $1.32B | -50.31% | 0.00% |
BP | -9.11% | $83.56B | -11.74% | 5.67% |
K | -8.30% | $28.31B | +49.49% | 2.75% |
HEES | -8.18% | $3.23B | +62.24% | 1.25% |
VERI | -7.65% | $144.04M | +86.71% | 0.00% |
SYPR | -7.07% | $51.80M | +18.42% | 0.00% |
HPK | -6.93% | $1.73B | -2.91% | 1.16% |
GPRK | -6.91% | $460.97M | +5.01% | 6.32% |
TRVG | -6.90% | $84.86M | +50.61% | 0.00% |
IEP | -6.75% | $4.92B | -49.38% | 35.71% |
CVI | -6.01% | $1.85B | -47.49% | 8.10% |
HII | -5.95% | $6.25B | -41.30% | 3.23% |
INVX | -5.87% | $1.05B | -22.88% | 0.00% |
BF.A | -5.60% | $14.85B | -46.35% | 2.80% |
JBSS | -5.58% | $821.88M | -27.25% | 1.20% |
PRPO | -5.48% | $10.23M | +6.48% | 0.00% |
BF.B | -5.45% | $14.78B | -45.09% | 2.80% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
HRL | <0.01% | $16.02B | -0.98% | 3.89% |
MNSO | -0.03% | $7.09B | +41.95% | 1.18% |
FUBO | -0.05% | $1.37B | +106.12% | 0.00% |
AVNW | -0.05% | $311.65M | -25.77% | 0.00% |
CAG | -0.06% | $11.94B | -11.00% | 5.57% |
BRY | 0.06% | $329.30M | -32.80% | 10.26% |
FIZZ | -0.08% | $3.76B | -8.84% | 0.00% |
FATBB | 0.13% | $73.90M | -10.95% | 13.02% |
DKL | 0.15% | $2.28B | -4.17% | 10.30% |
MUR | 0.16% | $3.84B | -31.17% | 4.46% |
DT | 0.23% | $18.00B | +7.22% | 0.00% |
MNOV | -0.23% | $94.08M | +37.01% | 0.00% |
POAI | 0.31% | $10.20M | -47.60% | 0.00% |
PRT | 0.31% | $51.34M | -2.99% | 10.05% |
GFI | 0.31% | $16.67B | +35.49% | 2.06% |
MSDL | 0.34% | $1.84B | +3.39% | 9.63% |
DINO | 0.36% | $6.90B | -37.36% | 5.43% |
NTNX | 0.44% | $18.98B | +20.88% | 0.00% |
PDD | 0.45% | $156.54B | -11.00% | 0.00% |
BOOM | 0.46% | $158.41M | -54.59% | 0.00% |
Current Value
$43.381 Year Return
Current Value
$43.381 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
KYMR | 43.50% | $2.53B | +14.89% | 0.00% |
RYTM | 41.96% | $3.69B | +26.20% | 0.00% |
IDYA | 40.62% | $2.07B | -46.52% | 0.00% |
DYN | 39.21% | $1.71B | -26.26% | 0.00% |
CRNX | 39.15% | $3.59B | +0.66% | 0.00% |
RARE | 37.40% | $4.23B | +0.73% | 0.00% |
RCKT | 37.14% | $1.13B | -63.60% | 0.00% |
ALLO | 36.78% | $335.48M | -63.39% | 0.00% |
ACLX | 36.35% | $3.69B | +10.85% | 0.00% |
PRTA | 36.01% | $777.00M | -47.36% | 0.00% |
RNA | 35.78% | $4.19B | +180.66% | 0.00% |
DAWN | 35.30% | $1.26B | -17.86% | 0.00% |
SNDX | 35.22% | $1.35B | -28.09% | 0.00% |
IMVT | 34.87% | $3.46B | -42.27% | 0.00% |
NRIX | 33.82% | $1.44B | +120.88% | 0.00% |
DNLI | 33.51% | $3.24B | +30.99% | 0.00% |
EWTX | 33.40% | $2.72B | +44.83% | 0.00% |
AGIO | 33.28% | $1.96B | +42.35% | 0.00% |
NMAI | 33.27% | - | - | 13.20% |
ATXS | 33.00% | $420.43M | -51.18% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -27.98% | $195.31M | 0.85% |
TAIL | -23.20% | $65.47M | 0.59% |
BTAL | -22.90% | $272.15M | 1.43% |
TPMN | -20.49% | $33.98M | 0.65% |
BNO | -12.30% | $96.30M | 1% |
USO | -11.36% | $1.07B | 0.6% |
OILK | -10.63% | $73.58M | 0.69% |
USL | -10.40% | $47.31M | 0.85% |
DBE | -10.27% | $53.97M | 0.77% |
TAXF | -9.84% | $524.56M | 0.29% |
DBO | -9.60% | $185.78M | 0.77% |
GSG | -9.36% | $1.05B | 0.75% |
USDU | -8.66% | $294.70M | 0.5% |
COMT | -8.57% | $728.03M | 0.48% |
UGA | -8.18% | $101.57M | 0.97% |
XHLF | -7.88% | $1.07B | 0.03% |
BSMR | -7.76% | $219.86M | 0.18% |
UUP | -7.28% | $402.74M | 0.77% |
BSSX | -6.94% | $69.84M | 0.18% |
IBMO | -6.85% | $509.34M | 0.18% |